Gilead Sciences (GILD) Other Gross PP&E Adjustments (2009 - 2026)

Gilead Sciences (GILD) reported Other Gross PP&E Adjustments of $8.4 billion for Q1 2026, up 5.76% on a YoY basis from $8.0 billion in Q1 2025, and up 334.8% quarter-over-quarter from $1.9 billion in Q4 2025.

Gilead Sciences (GILD) Other Gross PP&E Adjustments (2009 - 2026) Analysis & Trends

Gilead Sciences has reported Other Gross PP&E Adjustments for 18 years, with the latest figure at $8.4 billion in Q1 2026.

  • For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 5.76% year-over-year to $8.4 billion; the trailing twelve-month figure through Mar 2026 stood at $8.4 billion (up 5.76% YoY), and the FY2025 full-year result was $1.9 billion, up 18.33% from the prior year.
  • Other Gross PP&E Adjustments for Q1 2026 stood at $8.4 billion, up from $1.9 billion in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $8.4 billion in Q1 2026, with the low at -$1.8 billion in Q1 2023.
  • Historically, Other Gross PP&E Adjustments has averaged $2.3 billion across 5 years, with a median of $1.0 billion in 2022.
  • Annual changes were most pronounced in 2023 — Other Gross PP&E Adjustments sank 34.38% — and 2024, when it jumped 45.25%.
  • Gilead Sciences' Other Gross PP&E Adjustments stood at $937.0 million in 2022, then increased by 20.28% to $1.1 billion in 2023, then jumped by 45.25% to $1.6 billion in 2024, then advanced by 18.33% to $1.9 billion in 2025, then jumped by 334.8% to $8.4 billion in 2026.
  • The last three Other Gross PP&E Adjustments figures came in at $8.4 billion (Q1 2026), $1.9 billion (Q4 2025), and $8.2 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Gross PP&E Adjustments (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn -941.03 Mn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn -
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn 49.60 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn -
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn -
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn -2.70 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn 8.42 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn -1.53 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 8.42 Bn
Mar 31, 2026 8.42 Bn
Dec 31, 2025 1.94 Bn
Dec 31, 2025 1.94 Bn
Sep 30, 2025 8.19 Bn
Sep 30, 2025 8.19 Bn
Jun 30, 2025 8.08 Bn
Jun 30, 2025 8.08 Bn
Mar 31, 2025 7.96 Bn
Mar 31, 2025 7.96 Bn
Dec 31, 2024 1.64 Bn
Dec 31, 2024 1.64 Bn
Dec 31, 2023 1.13 Bn
Dec 31, 2023 1.13 Bn
Sep 30, 2023 -598.00 Mn
Sep 30, 2023 -598.00 Mn
Jun 30, 2023 -1.20 Bn
Jun 30, 2023 -1.20 Bn
Mar 31, 2023 -1.79 Bn
Mar 31, 2023 -1.79 Bn